Core Viewpoint - argenx SE is holding its Annual General Meeting on May 6, 2026, to discuss key agenda items including the adoption of the 2025 annual accounts and changes to the Board of Directors [1][3]. Meeting Details - The Annual General Meeting will take place at 13:00 CET at the Hilton Amsterdam Schiphol [1]. - Shareholders and other meeting rights holders are invited to attend, with details available on the argenx website [2]. Agenda Items - The agenda includes the discussion and adoption of the 2025 annual accounts, an advisory vote on the 2025 remuneration report, discharge of directors for their 2025 duties, and authorization for the Board to issue shares [3]. - Proposed changes to the Board include the retirement of Jim Daly as non-executive director and Chair of the Commercialization Committee, effective May 6, 2026 [3][4]. - The Board is currently exploring succession options for Jim Daly [3]. Board Appointments - Karen Massey is appointed as executive director for a term of 4 years [8]. - Tim Van Hauwermeiren is appointed as non-executive director for a term of 4 years [8]. - Ana Céspedes and Camilla Sylvest are re-appointed as non-executive directors for terms of 4 years [8]. - Pamela Klein is re-appointed as a non-executive director for a term of 2 years [8]. Company Overview - argenx is a global immunology company focused on severe autoimmune diseases, partnering with academic researchers to develop novel antibody-based medicines [6]. - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its potential in various serious autoimmune diseases [6].

Press releaseParis, 20 March 2026 Orange Board of Directors appoints Frédéric Sanchez as Chairman The Board of Directors of Orange has decided to appoint Frédéric Sanchez, an independent director of Orange since 2020 and Chair of the Strategy and Technology Committee, as Chairman of the Board of Directors of Orange at the close of the Annual Shareholders’ Meeting to be held on 19 May 2026. This decision is based on the recommendations of the Governance, Corporate Social and Environmental Responsibility Com ...

Core Insights - JP3E Holdings Inc. has acquired a 61% controlling interest in Demora Foundation and a 51% controlling interest in Mammoth Labs Inc. in exchange for 300 million restricted JPTE shares, establishing a significant foothold in the RWA and VWA tokenization markets [1][2] Group 1: Acquisition Details - The acquisition includes 300 million shares, with 100 million shares coming from previously issued shares to Khan Gallery [1] - Demora Foundation is positioned as the institutional RWA and VWA tokenization platform for JP3E's K2Global SMB 500 program, targeting a $100 trillion RWA total addressable market and a $5 trillion+ VWA total addressable market by 2030 [1][2] Group 2: Market Potential - The total addressable market for RWA is defined as $100 trillion by 2030, covering sectors such as commodities, infrastructure, energy, real estate, and manufacturing [2] - The VWA market is projected to exceed $5 trillion by 2030, with specific segments including AI Economy ($1.5 trillion), Creator Economy ($1 trillion), and Digital IP ($800 billion) [2] Group 3: Financial Projections - Capturing just 0.0001% of the $100 trillion RWA market could generate $10 billion in tokenized assets, supporting a network value target of $10 billion for Demora Chain [2] - The K2Global platform aims for a market cap of over $2 billion in RWA/VWA by 2028, focusing on 500 Korean SMBs across three US Innovation Cities [2][4] Group 4: Operational Framework - Demora Foundation will serve as the governance entity and tokenization platform for the Demora Chain, facilitating the issuance of various RWA and VWA token types [4][10] - The K2Global platform utilizes a proprietary KWAVE AI Engine to evaluate potential SMBs for onboarding, with current metrics showing a KWAVE Score of 94.2 and $4.8 billion in RWA tokenized [3][5] Group 5: Governance and Leadership - Baek Jong Yun has been appointed to the JP3E Board of Directors, with John Park serving as Chairman of the Demora Foundation [9] - The governance structure includes executives from Mammoth Labs, ensuring integration and oversight of the tokenization platform [9][8]

Core Viewpoint - MAX Power Mining Corp. successfully closed a private placement of units, raising approximately $20.5 million, marking the largest fundraising in the company's history, following the Lawson Discovery of Canada's first confirmed Natural Hydrogen subsurface system [1][2]. Group 1: Offering Details - The private placement involved the sale of 15,805,624 units at a price of C$1.30 per unit, resulting in total gross proceeds of $20,547,311.20 [2]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of C$1.80 for up to 24 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to several key areas: 1. Analytical testing, resource modeling, and estimation of the Lawson Natural Hydrogen Discovery [3]. 2. Acquisition of 2D and 3D seismic data across various targets in Saskatchewan [3]. 3. Drilling of additional wells [3]. 4. General corporate purposes, including administrative and marketing expenses [3]. Group 3: Participation and Related-Party Transactions - Eric Sprott, through 2176423 Ontario Ltd., acquired 3,538,461 units for a total of $4,599,999.30 [4]. - Certain officers, directors, and insiders of the company purchased an aggregate of 3,620,010 units, which constitutes a related-party transaction under Multilateral Instrument 61-101 [5]. Group 4: Regulatory Compliance - The units were offered under the Listed Issuer Financing Exemption, applicable in all provinces of Canada except Quebec, and in other qualifying jurisdictions, including the United States [6]. - The securities issued will not be subject to a statutory hold period under Canadian securities laws [6]. Group 5: Company Overview - MAX Power is focused on mineral and energy exploration, particularly in the decarbonization sector, with significant land positions in Saskatchewan for Natural Hydrogen exploration [11]. - The Lawson Discovery represents Canada's first confirmed subsurface Natural Hydrogen system, validated by independent labs [11]. - The company holds approximately 1.3 million acres of permits and an additional 5.7 million acres under application for exploration [11].

Core Viewpoint - Genco Shipping & Trading Limited's Board of Directors believes that Diana's indicative proposal does not meet the standards for maximizing shareholder value and is below the company's intrinsic value and NAV [1] Group 1: Company Overview - Genco Shipping & Trading Limited is the largest U.S. headquartered drybulk shipowner focused on global transportation of commodities, including iron ore, coal, grain, and steel products [3] - The company operates a modern fleet of 45 vessels with an average age of 12.8 years and an aggregate capacity of approximately 5,044,000 deadweight tons (dwt) [3] Group 2: Proposal Response - The Board of Directors is open to engaging with Diana if an offer is made that appropriately reflects Genco's intrinsic value and the potential upside of the business [2] - Jefferies LLC is acting as the financial advisor, while Herbert Smith Freehills Kramer (US) LLP and Sidley Austin LLP are serving as legal counsel to Genco [2]

Core Viewpoint - Sanuwave Health, Inc. will present its Q4 and Full Year 2025 financial results in a live conference call scheduled for March 27, 2026 [1] Group 1: Conference Call Details - The conference call will take place at 8:30 AM (ET) [1] - Participants can access the call via toll-free number 1-800-343-4136 or international number 1-203-518-9843 [1] - A replay of the call will be available until April 10, 2026, with access numbers provided [2] Group 2: Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [2][3] - The company's wound care portfolio includes regenerative medicine products that assist in restoring normal healing processes [3] - Sanuwave applies its patented energy transfer technologies across various medical fields, including wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions [3]

Group 1 - The Combined Shareholders' Meeting of SCOR SE is scheduled for Tuesday, April 28, 2026, at 10:30 a.m. Paris time at the company's headquarters in Paris, France [2] - The notice of the meeting has been published in the Bulletin des Annonces Légales Obligatoires and includes the agenda and resolutions for shareholder approval [2] - Shareholders can obtain proxy or postal voting forms through their financial intermediaries or directly if they hold registered shares [3] Group 2 - SCOR is a leading global reinsurer, providing a diverse range of reinsurance and insurance solutions to manage risk [6] - The company generated premiums of EUR 18.7 billion in 2025 and operates in over 150 countries with more than 35 offices worldwide [7] - All content published by SCOR since January 1, 2024, is certified with Wiztrust for authenticity verification [8]

Group 1 - Fagron received a transparency notification from Aberdeen Group plc indicating that its shareholding has fallen below the 3% disclosure threshold due to a disposal of voting securities [8] - As of 13 March 2026, Aberdeen Group plc holds a total of 2,195,403 shares in Fagron, which corresponds to 2.98% of the total voting rights based on 73,668,904 outstanding voting rights [8] - The shares are held through two entities: 1,850,845 shares through abrdn Investment Management Limited and 344,558 shares through abrdn Investments Limited [8] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in over 38 countries [3] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4]

Group 1 - Ilkka Oyj acquired 2,981 shares at an average price of EUR 4.1793 per share, totaling EUR 12,458.49 on 20 March 2026 [1] - After the acquisition, Ilkka Oyj holds a total of 129,926 treasury shares [1] Group 2 - Ilkka is a marketing and technology company that provides professional, data, and technology services in digital marketing and communications [2] - The core of Ilkka's business includes the software company Liana, its Swedish subsidiary Ungapped, and other specialized agencies in data-driven sales and marketing, WordPress digital services, social media marketing, and B2B marketing [2] - The company employs approximately 330 marketing, technology, and data experts and focuses on international markets, particularly Sweden and emerging markets in the Middle East [2]

Core Viewpoint - SPIE has successfully completed its share buyback program, aimed at mitigating the dilutive effects of new share issuances related to employee shareholding and incentive plans [1][2]. Group 1: Share Buyback Program - The share buyback program was initiated on March 9, 2026, with a maximum of 1,250,000 shares to be repurchased [1]. - Between March 9 and March 19, 2026, SPIE repurchased the full amount of 1,250,000 shares [2]. - The repurchased shares are set to be cancelled in the upcoming weeks [2]. Group 2: Company Overview - SPIE is recognized as the independent European leader in multi-technical services, focusing on energy and communications [3]. - The company employs 55,000 individuals and is actively involved in driving energy, digital, and industrial transitions [3]. - In 2025, SPIE reported consolidated revenue of €10.4 billion and consolidated EBITA of €793 million [3].